MEDIA RELEASE PR35618
The Breast Cancer Therapeutics Market in Australia
SYDNEY, Aug. 6 /PRNewswire-AsiaNet/ --
Growth in innovative targeted therapies set to drive breast
cancer therapeutics market in Australia
Rising public awareness of breast cancer and available treatments have
increased revenues in the breast cancer therapeutics market in Australia. As
the most common cancer diagnosed in Australia's female population, the total
number of breast cancer patients in the country was 164,814 in 2008. This
figure is estimated to reach 304,511 patients by 2013. Globally, breast
cancer is second to lung cancer as the cause of death among women.
Initiatives such as the BreastScreen Australia program, which provides
free mammography services to aid in the early detection of breast cancer,
have resulted in oncologists seeing more early stage disease. This, combined
with aggressive and targeted therapy has, in turn, resulted in a reduction in
the number of locally-advanced and metastatic breast cancer patients in the
country.
The use of molecular targeted therapies as effective forms of cancer
therapy is becoming more prevalent. These therapies are specifically designed
to target cancer cells, while minimizing the adverse effects on normal cells
when compared to cytotoxic chemotherapeutic drugs. New offerings must
constitute therapies that will improve quality of life and survival rates if
they are to thrive in this highly competitive market.
"Biopharmaceutical companies are placing more emphasis on developing
targeted breast cancer therapies that offer patients not only increased
efficacy, but reduced side effects as well," explains Carole Gaffud, Frost &
Sullivan Research Analyst. "There are several new targeted therapies and
chemotherapy drugs under development, including Epotheliones and Vascular
Endothelial Growth Factor Receptor (VEGFR) inhibitors."
However, chemotherapy continues to be used widely for now. This may be
attributed to the fact that the use of targeted therapy is limited due to
access and affordability issues, thereby making those complements rather than
substitutes for chemotherapy. "Due to higher cost compared to cytotoxic and
hormonal therapies, the use of targeted therapies in Australia is and will
continue to be largely dependent on their price and availability on the
Pharmaceutical Benefits Scheme (PBS)," says Gaffud.
Currently, only Herceptin (for early stage breast cancer patients) and
Tykerb (for advanced/metastatic breast cancer patients) are subsidized
through the PBS. Nonetheless, innovative targeted therapies are showing great
promise and are being touted as the future of breast cancer treatment.
Combinations of these highly specific therapies with existing cytotoxic and
hormonal therapies will soon become the standard of oncology care.
Frost & Sullivan's latest research service on The Breast Cancer
Therapeutics Market in Australia provides competitive structure, market
analysis and future trends for the breast cancer drug therapies (cytotoxic,
hormonal and targeted) in Australia.
This analysis is available through our Pharmaceutical & Biotechnology
Growth Partnership Services programme. With continuous access to intelligence
and resources from all seven perspectives of the Complex Business Universe,
the Growth Partnership Services programme ensures that you and your Growth
Team(TM) are able to maintain a 360 Degree Perspective of the market. This
comprehensive, objective information allows your company to mitigate risk,
identify new opportunities, and drive effective strategies for growth.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best practice models to
drive the generation, evaluation and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 31 offices on six continents. To join our Growth Partnership,
Contact:
Jasminder Kaur
Corporate Communications -Healthcare, Asia Pacific
DID: +65 6890 0937
Email: jkaur@frost.com
Emmie Kaur
Corporate Communications -Healthcare, Asia Pacific
DID: +603 6204 5913
Email: emmie.kaur@frost.com
SOURCE: Frost & Sullivan
CONTACT: Jasminder Kaur,
+65 6890 0937,
jkaur@frost.com, or
Emmie Kaur,
+603 6204 5913,
emmie.kaur@frost.com,
both of Corporate Communications-Healthcare,
Asia Pacific of Frost & Sullivan
NEWS 
